MET and lung carcinoma: There is increasing emphasis on the importance of the c-Met/HGF pathway in lung cancer progression and promotion of resistance resulting from Met amplification, exon 14 mutation, or activation due to HGF expression [32,33,34], with small molecule Met inhibitors and anti-HGF antibodies now in clinical trials [35,36].